|
|
||||||||
The bee venom peptide, apamin, has been radiolabelled with 125I, the monoiodinated derivative purified, and its binding to intact guinea-pig liver cells studied. At 37 degrees C 125I-monoiodoapamin associated with, and dissociated from, guinea-pig hepatocytes remarkably rapidly. The association and dissociation rate constants were 1.4 X 10(8) M-1 s-1 and 0.035 s-1 respectively. Equilibrium binding studies demonstrated a saturable binding component compatible with 1:1 binding to a single class of site and having an equilibrium dissociation constant (KL) of 390 pM. The maximal binding capacity was 1.1 fmol mg-1 dry wt. of tissue. Unlabelled apamin displaced bound 125I-monoiodoapamin with a KI of 380 pM, which is consistent with the concentration of apamin required to inhibit Ca2+-activated K+ permeability (PK(Ca) ) in these cells. Inhibitable binding of 125I-monoiodoapamin to rat hepatocytes was much less than to guinea-pig hepatocytes and could not be reliably quantified. Neither was there any discernible inhibitable binding to human erythrocytes. This is in keeping with the reported lack of apamin-sensitive Ca2+-activated K+ channels in these cell types. Various agents were tested for their ability to inhibit monoiodoapamin binding to, and Ca2+-mediated K+ efflux from, guinea-pig hepatocytes. All compounds tested which inhibited binding also blocked K+ efflux at similar concentrations. TEA and quinine affected hepatocytes only at high concentration (KI = 5.8 and 0.51 mM respectively). 9-aminoacridine, quinacrine and chloroquine were slightly more effective (KI = 70-180 microM). By far the most active compounds (apart from apamin) were the neuromuscular blocking agents; tubocurarine, pancuronium and atracurium (KI = 7.5, 6.8 and 4.5 microM respectively). Gallamine was slightly less effective (KI = 14 microM) and decamethonium and hexamethonium much less so (KI = 620 and 760 microM respectively). 3,4-diaminopyridine, alpha-bungarotoxin and tetrodotoxin were among several compounds which showed little or no affinity for apamin binding sites or inhibition of K+ efflux in guinea-pig hepatocytes. The saturable binding of 125I-monoiodoapamin to guinea-pig hepatocytes corresponds to about 1700 sites per cell. Assuming, tentatively, that binding sites correspond to channels the rate of K+ loss observed following agonist action can readily be explained if these channels have unitary conductances in the range reported for PK(Ca) in other tissues.
This article has been cited by other articles:
![]() |
R. Roman, A. P. Feranchak, M. Troetsch, J. C. Dunkelberg, G. Kilic, T. Schlenker, J. Schaack, and J. G. Fitz Molecular characterization of volume-sensitive SKCa channels in human liver cell lines Am J Physiol Gastrointest Liver Physiol, January 1, 2002; 282(1): G116 - G122. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shah and D. G. Haylett Ca2+ Channels Involved in the Generation of the Slow Afterhyperpolarization in Cultured Rat Hippocampal Pyramidal Neurons J Neurophysiol, May 1, 2000; 83(5): 2554 - 2561. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stocker, M. Krause, and P. Pedarzani An apamin-sensitive Ca2+-activated K+ current in hippocampal pyramidal neurons PNAS, April 13, 1999; 96(8): 4662 - 4667. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Nuttle, A. L. Ligon, K. R. Farrell, and R. L. Hester Inhibition of phospholipase A2 attenuates functional hyperemia in the hamster cremaster muscle Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1289 - H1294. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Doorty, S. Bevan, J. D. F. Wadsworth, and P. N. Strong A Novel Small Conductance Ca2+-activated K+ Channel Blocker from Oxyuranus scutellatus Taipan Venom. RE-EVALUATION OF TAICATOXIN AS A SELECTIVE Ca2+ CHANNEL PROBE J. Biol. Chem., August 8, 1997; 272(32): 19925 - 19930. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lanzafame, A. Christopoulos, and F. Mitchelson Three Allosteric Modulators Act at a Common Site, Distinct from that of Competitive Antagonists, at Muscarinic Acetylcholine M2 Receptors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 278 - 285. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |